Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The objective of this phase-III trial is to compare the efficacy and safety of sorafenib in combination with capecitabine versus capecitabine in combination with placebo in the treatment of subjects with locally advanced or metastatic HER2-negative breast cancer who are resistant to or have failed prior taxane and an anthracycline or for whom further anthracycline therapy is not indicated. The primary efficacy endpoint is progression-free survival (PFS).
Critère d'inclusion
- Locally advanced or metastatic HER2-negative breast cancer